Working... Menu

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00345787
Recruitment Status : Completed
First Posted : June 29, 2006
Last Update Posted : April 15, 2008
Information provided by:
Mundipharma Pte Ltd.

Brief Summary:
The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.

Condition or disease Intervention/treatment Phase
Pain Osteoarthritis Drug: Placebo Drug: Buprenorphine Transdermal System Phase 3

Detailed Description:
The primary objective of this study is to evaluate the efficacy and safety of buprenorphine transdermal system (BTDS) compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee who have a sub-optimal response to their non-opioid analgesic treatment and require opioid analgesics for pain control.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 262 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Osteoarthritic Pain of the Hip or Knee
Study Start Date : May 2006
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: 0 Drug: Placebo
Corresponding placebo is applied for 12weeks

Experimental: 1 Drug: Buprenorphine Transdermal System
Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks

Primary Outcome Measures :
  1. The time to the development of inadequate analgesia [ Time Frame: Up to 12weeks ]

Secondary Outcome Measures :
  1. Percentage of subjects who developed inadequate analgesia, 'Average pain over the last 24 hours' scores [ Time Frame: 12weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females ages 40 years or older.
  • Clinical diagnosis of osteoarthritis (OA) of the hip or knee.

Exclusion Criteria:

  • Subjects who have a current or past history of chronic disease(s), in addition to OA, requiring frequent analgesic therapy (e.g. headache, fibromyalgia, gout, rheumatoid arthritis, low back pain, and diabetic neuropathy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00345787

Layout table for location information
Investigational Site
Nagoya, Aichi, Japan
Investigational Site
Okazaki, Aichi, Japan
Investigational Site
Ichikawa, Chiba, Japan
Investigational Site
Matsudo, Chiba, Japan
Investigational Site
Nagareyama, Chiba, Japan
Investigational Site
Annaka, Gunma, Japan
Investigational Site
Takasaki, Gunma, Japan
Investigational Site
Chitose, Hokkaido, Japan
Investigational Site
Sapporo, Hokkaido, Japan
Investigational Site
Kako, Hyogo, Japan
Investigational Site
Kobe, Hyogo, Japan
Investigational Site
Yokohama, Kanagawa, Japan
Investigational Site
Joyo, Kyoto, Japan
Investigational Site
Sendai, Miyagi, Japan
Investigational Site
Isahaya, Nagasaki, Japan
Investigational Site
Kasukabe, Saitama, Japan
Investigational Site
Koshigaya, Saitama, Japan
Investigational Site
Hikone, Shiga, Japan
Investigational Site
Adachi, Tokyo, Japan
Investigational Site
Arakawa, Tokyo, Japan
Investigational Site
Edogawa, Tokyo, Japan
Investigational Site
Koto, Tokyo, Japan
Investigational Site
Setagaya, Tokyo, Japan
Investigational Site
Suginami, Tokyo, Japan
Investigational Site
Himi, Toyama, Japan
Investigational Site
Kurobe, Toyama, Japan
Investigational Site
Fukui, Japan
Investigational Site
Osaka, Japan
Sponsors and Collaborators
Mundipharma K.K.
Layout table for investigator information
Study Chair: Mutsukuni Kataoka Department Head, Clinical Trial Operations, Clinical Development, Mundipharma K.K.

Layout table for additonal information
Responsible Party: Mutsukuni Kataoka, Mundipharma K.K. Identifier: NCT00345787     History of Changes
Other Study ID Numbers: BUP3801
First Posted: June 29, 2006    Key Record Dates
Last Update Posted: April 15, 2008
Last Verified: April 2008

Keywords provided by Mundipharma Pte Ltd.:
Osteoarthritic Pain

Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists